CLRB
NASDAQCellectar Biosciences Inc.
Cellectar Biosciences Inc. (CLRB) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for CLRB, including 2 press releases and news items and 1 earnings update. The most recent was published Nov 2, 2026.
CLRB rankings
Financial highlights
Full financials- Net income, TTM
- -$22.32M
- Cash
- $33.99M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks39+200%
2026-05-102026-11-01
Mix890d
- Other4(50%)
- SEC Filings2(25%)
- Offering1(13%)
- Earnings1(13%)
Latest news
25 items- PRCellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2026, and provide a corporate update on November 10, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Tuesday, November 10, 2026Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:Webcast:29257Click HERE A replay of the corporate presentation will be available on the Events section of the company’s Investor Relations website. About
- PRCellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a Range of B-cell Malignancies FLORHAM PARK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today reported results from a case study highlighting a durable complete response in a heavily pretreated patient with diffuse large B-cell lymphoma (DLBCL) treated with iopofosine I 131. The case study describes a 53-year-o
- PRCellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström MacroglobulinemiaSubgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months Initiation and site selections for Phase 3 confirmatory randomized clinical trial in post-first line, post-BTKi population evaluating Progression-Free Survival as primary endpoint underway; dosing of first patients expected in 1Q27 and application for U.S. accelerated market approval anticipated in 1H27 FLORHAM PARK, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development o
- PRCellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström MacroglobulinemiaDemonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Data Further Support Company’s Plans to Advance Iopofosine I 131 in Phase 3 Confirmatory Trial and Submit for U.S. Accelerated Market Approval in 1H27 FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that a subset analysis of data from the company’s Phase 2 CLOVER WaM clinical trial that sup
- SECSEC Form SCHEDULE 13G filed by Cellectar Biosciences Inc.SCHEDULE 13G - Cellectar Biosciences, Inc. (0001279704) (Subject)
- SECCellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
- PRCellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesSite Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program Presented Data from CLOVER WaM Trial of Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) at the American Society of Clinical Oncology 2026 Annual Meeting Initiated Enrollment and Dosed First Patients in Phase 1b Clinical Trial of CLR 125 in Triple Negative Breast Cancer Announced Publication of Phase 1 Data in Peer-Reviewed Journal Cancers Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences,
- SECSEC Form 10-Q filed by Cellectar Biosciences Inc.10-Q - Cellectar Biosciences, Inc. (0001279704) (Filer)
- PRCellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursday, August 13, 2026Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:26325Webcast:Click HERE A replay of the corporate presentation will be available on the Events section of the Company’s Investor Relations website. About Celle
- PRCellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal CancersDemonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma Publication Supports Continued Development of Iopofosine I 131 as a Novel Targeted Radiotherapeutic Across Multiple B-Cell Malignancies FLORHAM PARK, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the publication of results from a Phase 1 dose-escalation study evaluating iopofosine I 131 in combination with low-dose dexamethasone in 31 patients with heavily pretreated relapsed/refractory multiple myelo
- INSIDERAmendment: SEC Form 4 filed by Consultant Loren Stefan4/A - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- SECCellectar Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
- INSIDERSEC Form 4 filed by CFO Kolean Chad J4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- INSIDERSEC Form 4 filed by Director Driscoll Frederick W4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- INSIDERSEC Form 4 filed by Director Chanan-Khan Asher4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Caruso James V4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- INSIDERSEC Form 4 filed by Director Gu Andrew4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Longcor Jarrod4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- INSIDERSEC Form 4 filed by Director Swirsky Douglas J4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- INSIDERSEC Form 4 filed by Director Neis John4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- INSIDERSEC Form 4 filed by Consultant Loren Stefan4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gu Andrew3 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Cellectar Biosciences Inc.SCHEDULE 13G - Cellectar Biosciences, Inc. (0001279704) (Subject)
- SECSEC Form 424B3 filed by Cellectar Biosciences Inc.424B3 - Cellectar Biosciences, Inc. (0001279704) (Filer)
- SECSEC Form EFFECT filed by Cellectar Biosciences Inc.EFFECT - Cellectar Biosciences, Inc. (0001279704) (Filer)
CLRB FAQ
9 questionsWhat does Cellectar Biosciences Inc. do?
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic...What is the latest news on CLRB?
In the last 30 days Quantisnow tracked 3 wire items for CLRB: 2 press releases and news items and 1 earnings update. The most recent was published on November 2, 2026.Is CLRB profitable?
No. Cellectar Biosciences Inc. reported a net loss of $22.32M for the twelve months ended Jun 30, 2026.How much cash and debt does CLRB have?
Cellectar Biosciences Inc. reported $33.99M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does CLRB stock trade?
Cellectar Biosciences Inc. (CLRB) is listed on NASDAQ.What sector and industry is CLRB in?
Cellectar Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CLRB?
Across the last 3 analyst actions on Cellectar Biosciences Inc., there was 1 upgrade and 0 downgrades. The most recent action was from Ladenburg Thalmann: Buy with a $10.00 price target on 2026-05-15. Recent price targets range from $10.00 to $13.00.What companies are similar to CLRB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CLRB side-by-side with any of them on Quantisnow.How can I track CLRB on Quantisnow?
Quantisnow aggregates Cellectar Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLRB to receive live email and push alerts on every new disclosure.